戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 and specific mRNA, of the cDNA encoding this platelet inhibitor.
2  the well appreciated action of aspirin as a platelet inhibitor.
3 years (SD 9), 85% were male, 92% were taking platelet inhibitors, 62% beta blockers, and 58% lipid-lo
4 Arginine-glycine-aspartic acid (RGD)-mimetic platelet inhibitors act by occupying the RGD recognition
5 d platelet agonist; prostacyclin is a potent platelet inhibitor and vasodilator.
6    An inverse association between the use of platelet inhibitors and the risk of cancer has been repo
7 n K antagonists, direct oral anticoagulants, platelet inhibitors, and combinations of antithrombotic
8 tial and personalized use of anticoagulants, platelet inhibitors, and devices is recommended and revi
9 requently prescribed aspirin, beta-blockers, platelet inhibitors, and statins (all p < 0.0001).
10                                              Platelet inhibitors are the mainstay of drug therapy to
11       These represent intriguing targets for platelet inhibitor development or shed light on the over
12 d the ability of a new glycoprotein IIb/IIIa platelet inhibitor DMP-444, labeled with technetium (Tc)
13 0(9)/L) (HR, 2.21 [95% CI = 1.24, 3.94]) and platelet inhibitor drugs (HR, 1.69 [95% CI = 1.11, 2.56]
14             This protein, named the hookworm platelet inhibitor, has an estimated molecular mass of 1
15  suggesting a biologic role for the hookworm platelet inhibitor in vivo.
16                              Addition of the platelet inhibitor indomethacin to vitamin E simultaneou
17                                 Furthermore, platelet inhibitor intake was also associated with an in
18                              The presence of platelet inhibitor intake was associated with a signific
19 ction platelet depletion or treatment with a platelet inhibitor is not protective.
20      One of the most important physiological platelet inhibitors is endothelium-derived prostacyclin
21 opose that a combination of antioxidants and platelet inhibitors might be rationally evaluated in the
22  collagen was substantially inhibited by the platelet inhibitors prostaglandin E1 and theophylline, t
23                                              Platelet inhibitors such as aspirin and/or P2Y12 antagon
24 potent, rapid-acting, reversible intravenous platelet inhibitor that was tested for percutaneous coro
25                                 Conventional platelet inhibitor therapy provides early but not persis
26  direct thrombin inhibitor (DTI) dabigatran; platelet inhibitors: thienopyridines (clopidogrel, ticlo
27 f direct thrombin inhibitors or glycoprotein platelet inhibitors to intravenous thrombolysis in patie
28  risk of intracranial hemorrhage, the use of platelet inhibitors was associated with delayed need for
29      In this retrospective study, the use of platelet inhibitors was not associated with an increased
30                                      Several platelet inhibitors were examined in a tissue factor (TF